Healthcare

Spread evenly over its seven-year term, the A$43 million works out at about A$6.1 million a year, although the company did not give a year-by-year breakdown. It described the arrangement as a transactional licensing model, and its summary of the deal says the model …

Sammells called FY26 the first full 12-month period operating as a merged group, at the second AGM since the merger. He said a prospectus issued ahead of the merger disclosed pro forma EBIT of $605 million for FY24. Net debt at year end was …

Group revenue of US$245 million compares with US$206 million in Q3 2025 and US$247 million in Q2 2026. Precision Medicine revenue, which Telix said primarily reflects sales of Illuccix and Gozellix, was US$201 million, against US$155 million a year earlier and US$202 million in …

CurveBeam AI, headquartered in Melbourne with global operations in Hatfield, Pennsylvania, develops point-of-care CT imaging equipment and AI-enabled software for clinical assessment. Its HiRise system is a weight-bearing CT device, and the company is also developing CT-based bone mineral density (BMD) technology.

Cynata’s core asset is the Cymerus platform, which the company describes as a differentiated approach to manufacturing mesenchymal stromal cells at commercial scale from a single, consistent cell source. Its Board is currently focused on evaluating future development pathways for the technology and on …

Ceryvyn’s lead program is CYV-101, a first-in-class fusion protein designed to bind and neutralise VEGF-C and VEGF-D, signalling proteins that activate VEGFR-3. The molecule was previously known as OPT-302 and was developed for ophthalmology. The company is now developing CYV-101 as an inhaled therapy …

SomnoMed designs and manufactures oral appliance therapy devices that are used to treat obstructive sleep apnea and other sleep-related breathing disorders. Roughly 95% of its revenue is earned in currencies other than the Australian dollar, with Europe, North America and Asia Pacific its main …